Nektar Therapeutics (Nasdaq: NKTR) announced that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California. NKTR-102 is a novel topoisomerase I inhibitor designed using Nektar's proprietary polymer conjugate technology, and is being developed in multiple tumor settings...
More...
iHav.net - Your Uncensored Offtopic Community
If this is your first visit, please click the Sign Up now button to begin the process of creating your account so you can begin posting on our forums! The Sign Up process will only take up about a minute of two of your time.
|
|
|
Results 1 to 1 of 1
-
09-10-2011, 08:56 AM #1Senior Member
- Join Date
- Mar 2008
- Posts
- 12,518
- Downloads
- 0
- Uploads
- 0
Positive Results From Phase 2 Clinical Study Of NKTR-102 In Metastatic Breast Cancer
Reply With QuoteSimilar Threads
-
Promising Targeted Therapy For Her2-Positive Metastatic Breast Cancer
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 10-09-2010, 01:00 PM -
Positive Clinical Results In Pill-Plus™ Oral Contraceptive Study Could Mean An End To
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 07-04-2010, 01:00 PM -
Poniard Pharmaceuticals Presents Positive Survival Data From A Phase 2 Clinical Study
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 03-06-2010, 01:00 PM -
Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vac
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 02-13-2010, 01:00 PM -
Enzon Opens A Phase 2 Study Of PEG-SN38 For Metastatic Breast Cancer
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 01-07-2010, 01:31 PM
Bookmarks